Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or-3 Infections: A Systematic Review and Meta-Analysis

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

BAYATPOOR MOHAMMAD EHSAN; KHOSRAVI MOHAMMAD HOSSEIN; SHARAFI HEIDAR; REZAEE ZAVAREH MOHAMMAD SAEID; BEHNAVA BITA; ALAVIAN SEYED MOAYED

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Archives of Clinical Infectious Diseases Year:2019 | Volume:14 | Issue:1 Page(s): 0-0

Download Full-Text

View:

134

Download:

Cites:

Information Journal Paper

Title

Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or-3 Infections: A Systematic Review and Meta-Analysis

Author(s)

Keywords

Hepatitis C

Sofosbuvir

Ribavirin

Pegylated-Interferon

Meta-Analysis

Abstract

Background: Direct-acting antiviral agents (DAAs) have changed the treatment landscape of Hepatitis C virus (HCV) infection. Sofosbuvir (SOF), as a DAA inhibiting HCV NS5B polymerase, has found a remarkable contribution to the treatment regimens of HCV genotype-2 (HCV-2) and-3 infections. Objectives: In this Meta-Analysis, we aimed to evaluate the eﬃ cacy of the combination of SOF and Ribavirin (RBV) with or without Pegylated-Interferon (PegIFN) in the treatment of HCV-2 and-3 infections. Methods: In this Meta-Analysis, we searched electronic databases including PubMed, Scopus, ScienceDirect, and Web of Science using appropriate and relevant keywords. Based on the results of the heterogeneity test (chi-squared and I-squared), ﬁ xed-or randomeﬀ ects models were used to calculate the pooled sustained virological response (SVR) rates. Results: After removing duplicates and screening of 1408 articles, 16 studies were included in the quantitative synthesis. The pooled SVR rates calculated for the treatment of patients suﬀ ering HCV-2 infection were 91. 2% (95% CI: 86. 6%-95. 8%) using the SOF + RBV regimen for 12 weeks and 92. 6% (95% CI: 87. 1%-98. 1%) using the SOF + RBV + PegIFN regimen for 12 weeks. The pooled SVR calculated for the treatment of patients suﬀ ering HCV-3 infection was 53. 1% (95% CI: 41%-65. 1%) using the SOF + RBV regimen for 12 weeks, 81. 6% (95% CI: 74. 4%-88. 7%) using the SOF + RBV regimen for 24 weeks, and 93. 8% (95% CI: 86. 9%-100%) using the SOF + RBV + PegIFN regimen for 12 weeks. Conclusions: The combination of SOF and BV with or without PegIFN for 12 weeks is highly eﬃ cacious (> 90%) for the treatment of patients with HCV-2 infection. However, for the treatment of patients with HCV-3 infection only would 12 weeks of SOF + PegIFN + RBV result in > 90% treatment success.

Cites

No record.

References

No record.

Cite

APA: Copy

SHARAFI, HEIDAR, BEHNAVA, BITA, & ALAVIAN, SEYED MOAYED. (2019). Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or-3 Infections: A Systematic Review and Meta-Analysis. ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 14(1), 0-0. SID. https://sid.ir/paper/745423/en

Vancouver: Copy

SHARAFI HEIDAR, BEHNAVA BITA, ALAVIAN SEYED MOAYED. Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or-3 Infections: A Systematic Review and Meta-Analysis. ARCHIVES OF CLINICAL INFECTIOUS DISEASES[Internet]. 2019;14(1):0-0. Available from: https://sid.ir/paper/745423/en

IEEE: Copy

HEIDAR SHARAFI, BITA BEHNAVA, and SEYED MOAYED ALAVIAN, “Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or-3 Infections: A Systematic Review and Meta-Analysis,” ARCHIVES OF CLINICAL INFECTIOUS DISEASES, vol. 14, no. 1, pp. 0–0, 2019, [Online]. Available: https://sid.ir/paper/745423/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops